Literature DB >> 20534722

Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.

Gang Xi1, Xinchun Shen, Yashwanth Radhakrishnan, Laura Maile, David Clemmons.   

Abstract

Hyperglycemia has been shown to induce the p66shc expression leading to increased reactive oxygen species (ROS) generation and apoptosis. In the present study, we demonstrated that hyperglycemia induced p66shc expression in vascular smooth muscle cells. This induction was associated with an increase in apoptosis as assessed by the increase of capspase-3 enzymatic activity, cleaved caspase-3 protein, and the number of dead cells. The ability of IGF-I to inhibit apoptosis was also attenuated. Further studies showed that hyperglycemia-induced p66shc inhibited IGF-I-stimulated phosphoinositide (PI)-3 kinase and AKT activation. Mechanistic studies showed that knockdown of p66shc enhanced IGF-I-stimulated SHPS-1/p85, p85/SHP-2, and p85/Grb2 association, all of which are required for PI-3 kinase/AKT activation. These responses were attenuated by overexpression of p66shc. IGF-I-stimulated p85 and AKT recruitment to the cell membrane fraction was altered in the same manner. Disruption of p66shc-Src interaction using either a blocking peptide or by expressing a p66shc mutant that did not bind to Src rescued IGF-I-stimulated PI-3 kinase/AKT activation as well as IGF-I-dependent cell survival. Although the highest absolute level of ROS was detected in p66shc-overexpressing cells, the relative increase in ROS induced by hyperglycemia was independent of p66shc expression. Taken together, our data suggest that the increase in p66shc that occurs in response to hyperglycemia is functioning to inhibit IGF-I-stimulated signaling and that the incremental increase in SMC sensitivity to IGF-I stimulation that occurs in response to p66shc induction of ROS is not sufficient to overcome the inhibitory effect of p66shc on Src kinase activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534722      PMCID: PMC2940520          DOI: 10.1210/en.2010-0242

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  53 in total

1.  Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I.

Authors:  Laura A Maile; Byron E Capps; Yan Ling; Gang Xi; David R Clemmons
Journal:  Endocrinology       Date:  2007-01-25       Impact factor: 4.736

2.  Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells.

Authors:  T S Schwab; B B Madison; A R Grauman; E L Feldman
Journal:  Apoptosis       Date:  2005-08       Impact factor: 4.677

3.  The role of Src kinase in insulin-like growth factor-dependent mitogenic signaling in vascular smooth muscle cells.

Authors:  Jaroslava Lieskovska; Yan Ling; Jane Badley-Clarke; David R Clemmons
Journal:  J Biol Chem       Date:  2006-07-05       Impact factor: 5.157

4.  Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene.

Authors:  Marcello Rota; Nicole LeCapitaine; Toru Hosoda; Alessandro Boni; Antonella De Angelis; Maria Elena Padin-Iruegas; Grazia Esposito; Serena Vitale; Konrad Urbanek; Claudia Casarsa; Marco Giorgio; Thomas F Lüscher; Pier Giuseppe Pelicci; Piero Anversa; Annarosa Leri; Jan Kajstura
Journal:  Circ Res       Date:  2006-06-08       Impact factor: 17.367

5.  Mechanism of insulin-like growth factor I-mediated proliferation of adult neural progenitor cells: role of Akt.

Authors:  Haviryaji S G Kalluri; Raghu Vemuganti; Robert J Dempsey
Journal:  Eur J Neurosci       Date:  2007-02       Impact factor: 3.386

6.  Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling.

Authors:  K S Ravichandran; V Igras; S E Shoelson; S W Fesik; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 7.  Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein.

Authors:  Francesco Cosentino; Pietro Francia; Giovanni G Camici; Pier Giuseppe Pelicci; Thomas F Lüscher; Massimo Volpe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-12-27       Impact factor: 8.311

8.  p66shc negatively regulates insulin-like growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 membrane recruitment.

Authors:  Gang Xi; Xinchun Shen; David R Clemmons
Journal:  Mol Endocrinol       Date:  2008-07-07

9.  Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells.

Authors:  Yashwanth Radhakrishnan; Laura A Maile; Yan Ling; Lee M Graves; David R Clemmons
Journal:  J Biol Chem       Date:  2008-04-16       Impact factor: 5.157

10.  Ablation of the gene encoding p66Shc protects mice against AGE-induced glomerulopathy by preventing oxidant-dependent tissue injury and further AGE accumulation.

Authors:  S Menini; C Iacobini; C Ricci; G Oddi; C Pesce; F Pugliese; K Block; H E Abboud; M Giorgio; E Migliaccio; P G Pelicci; G Pugliese
Journal:  Diabetologia       Date:  2007-07-05       Impact factor: 10.122

View more
  11 in total

Review 1.  Receptor tyrosine kinase (RTK) signalling in the control of neural stem and progenitor cell (NSPC) development.

Authors:  Alexander Annenkov
Journal:  Mol Neurobiol       Date:  2013-08-28       Impact factor: 5.590

2.  The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.

Authors:  Eric Haines; Caroline Saucier; Audrey Claing
Journal:  J Biol Chem       Date:  2014-01-09       Impact factor: 5.157

3.  The adaptor protein p66Shc inhibits mTOR-dependent anabolic metabolism.

Authors:  Mohamed A Soliman; Anas M Abdel Rahman; Dudley W Lamming; Dudley A Lamming; Kivanç Birsoy; Judy Pawling; Maria E Frigolet; Huogen Lu; I George Fantus; Adrian Pasculescu; Yong Zheng; David M Sabatini; James W Dennis; Tony Pawson
Journal:  Sci Signal       Date:  2014-02-18       Impact factor: 8.192

Review 4.  Nutrient-sensing mTORC1: Integration of metabolic and autophagic signals.

Authors:  Valerie P Tan; Shigeki Miyamoto
Journal:  J Mol Cell Cardiol       Date:  2016-01-07       Impact factor: 5.000

5.  Hyperglycemia enhances IGF-I-stimulated Src activation via increasing Nox4-derived reactive oxygen species in a PKCζ-dependent manner in vascular smooth muscle cells.

Authors:  Gang Xi; Xinchun Shen; Laura A Maile; Christine Wai; Katherine Gollahon; David R Clemmons
Journal:  Diabetes       Date:  2011-12-06       Impact factor: 9.461

6.  Contribution of neural cell death to depressive phenotypes of streptozotocin-induced diabetic mice.

Authors:  Cheng Chen; Yun Wang; Juan Zhang; Lian Ma; Jiang Gu; Guyu Ho
Journal:  Dis Model Mech       Date:  2014-04-24       Impact factor: 5.758

7.  Role of p66shc in skeletal muscle function.

Authors:  Veronica Granatiero; Gaia Gherardi; Matteo Vianello; Elsa Salerno; Erika Zecchini; Luana Toniolo; Giorgia Pallafacchina; Marta Murgia; Bert Blaauw; Rosario Rizzuto; Cristina Mammucari
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 8.  P66Shc and vascular endothelial function.

Authors:  Santosh Kumar
Journal:  Biosci Rep       Date:  2019-04-30       Impact factor: 3.840

9.  Src tyrosine kinase signaling antagonizes nuclear localization of FOXO and inhibits its transcription factor activity.

Authors:  Margret H Bülow; Torsten R Bülow; Michael Hoch; Michael J Pankratz; Martin A Jünger
Journal:  Sci Rep       Date:  2014-02-11       Impact factor: 4.379

10.  Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes.

Authors:  Khurrum Shahzad; Ihsan Gadi; Sumra Nazir; Moh'd Mohanad Al-Dabet; Shrey Kohli; Fabian Bock; Lukas Breitenstein; Satish Ranjan; Tina Fuchs; Zuhir Halloul; Peter P Nawroth; Pier Giuseppe Pelicci; Ruediger C Braun-Dullaeus; Eric Camerer; Charles T Esmon; Berend Isermann
Journal:  Commun Biol       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.